Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday

Vistagen Therapeutics (NASDAQ:VTGN) will release its earnings data after the market closes on Tuesday, August 13th. Analysts expect Vistagen Therapeutics to post earnings of ($0.41) per share for the quarter.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Tuesday, June 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.09. Vistagen Therapeutics had a negative return on equity of 41.94% and a negative net margin of 2,759.59%. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.41 million. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Price Performance

VTGN stock opened at $3.20 on Wednesday. The firm has a market cap of $86.59 million, a P/E ratio of -1.55 and a beta of 0.75. The company’s 50-day moving average price is $3.58 and its two-hundred day moving average price is $4.32. Vistagen Therapeutics has a 12 month low of $2.45 and a 12 month high of $24.71.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.